Phase 3 readouts expected in 2028
Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2028, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.
Summary
721 studies (620 Phase 3, 101 Phase 2/3) across 453 drugs.
| Indication | Studies |
|---|---|
| Obesity | 71 |
| Non-Small Cell Lung Cancer | 44 |
| Type 2 Diabetes | 31 |
| Breast Cancer | 30 |
| HR+/HER2- Metastatic Breast Cancer | 16 |
| Atherosclerotic Cardiovascular Disease | 15 |
| Alzheimer's Disease | 14 |
| Colorectal Cancer | 13 |
| Multiple Myeloma | 12 |
| Ulcerative Colitis | 12 |
| Crohn's Disease | 10 |
| Acute Myeloid Leukemia | 9 |
January 2028
February 2028
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2028-02 (month only) | risankizumab | AbbVie, Boehringer Ingelheim | Crohn's Disease | Phase 3 | NCT04524611 |
| 2028-02 (month only) | Olezarsen | Ionis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ), Theratechnologies | Familial Chylomicronemia Syndrome | Phase 3 | NCT05130450 |
| 2028-02 (month only) | onabotulinumtoxinA | AbbVie | Buerger Disease, Raynaud Syndrome | Phase 3 | NCT05698979 |
| 2028-02 (month only) | Givinostat | Italfarmaco S.p.A., JCR Pharmaceuticals | Duchenne Muscular Dystrophy | Phase 3 | NCT05933057 |
| 2028-02 (month only) | Semaglutide (Ozempic) | Novo Nordisk | Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment | Phase 3 | NCT06788626 |
| 2028-02 (month only) | vunakizumab | Jiangsu Hengrui Pharmaceuticals | Active Non-radiographic Axial Spondyloarthritis | Phase 3 | NCT06860750 |
| 2028-02 (month only) | Rituximab | Biogen, Chugai Pharma, Roche | Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | NCT06983821 |
| 2028-02 (month only) | Dexamethasone | Cervicobrachial Neuralgia | Phase 3 | NCT07084285 | |
| 2028-02 (month only) | lonapegsomatropin | Ascendis Pharma A/S, Teijin, VISEN Pharmaceuticals | Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery | Phase 3 | NCT07221851 |
| 2028-02 (month only) | ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | Obesity | Phase 3 | NCT07284875 |
| 2028-02 (month only) | Brenipatide | Eli Lilly | Major Depressive Disorder | Phase 3 | NCT07412756 |
| 2028-02 (month only) | Methotrexate | Erosive Hand Osteoarthritis | Phase 2/3 | NCT07501507 | |
| 2028-02 (month only) | lebrikizumab | Almirall, Eli Lilly | Atopic Dermatitis | Phase 3 | NCT07873801 |
| 2028-02-01 | Letrozole | Novartis | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma | Phase 3 | NCT04111978 |
| 2028-02-01 | indacaterol maleate / mometasone furoate | Novartis | Asthma | Phase 3 | NCT05562466 |
| 2028-02-01 | Semaglutide (Ozempic) | Novo Nordisk | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese | Phase 3 | NCT05819853 |
| 2028-02-01 | Rilertinib (SH-1028) | Nanjing Sanhome Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT06080776 |
| 2028-02-01 | Ivosidenib | Servier | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | NCT06127407 |
| 2028-02-01 | Azacitidine | Bristol-Myers Squibb | Peripheral T Cell Lymphoma | Phase 2/3 | NCT07389616 |
| 2028-02-01 | Venetoclax, Azacitidine | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT07407660 |
| 2028-02-02 | Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07205822 |
| 2028-02-03 | Inclisiran, Pelacarsen | Alnylam Pharmaceuticals, Novartis, Ionis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT06813911 |
| 2028-02-04 | sonelokimab | MoonLake Immunotherapeutics | Psoriatic Arthritis | Phase 3 | NCT07223138 |
| 2028-02-07 | tezepelumab | Amgen, AstraZeneca | Asthma | Phase 3 | NCT07363642 |
| 2028-02-09 | Baxdrostat | AstraZeneca, Roche | Hypertension | Phase 3 | NCT07686120 |
| 2028-02-14 | Adebrelimab | Jiangsu Hengrui Pharmaceuticals | Ovarian Cancer Recurrent | Phase 2/3 | NCT06791460 |
| 2028-02-14 | JNJ-101556143 | Johnson & Johnson | Prostate Cancer | Phase 3 | NCT07906717 |
| 2028-02-15 | Osimertinib, Glumetinib | AstraZeneca, Haihe Biopharma, Taiho Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT06829459 |
| 2028-02-16 | Neratinib | Knight Therapeutics, Pierre Fabre Medicament, Puma Biotechnology | HER2-Positive Breast Cancer, Breast Cancer | Phase 3 | NCT05760612 |
| 2028-02-16 | Trontinemab | Roche | Alzheimer's Disease | Phase 3 | NCT07169578 |
| 2028-02-16 | Trontinemab | Roche | Alzheimer's Disease | Phase 3 | NCT07170150 |
| 2028-02-16 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07845500 |
| 2028-02-17 | Trastuzumab Deruxtecan | AstraZeneca, Daiichi Sankyo | Advanced Cancer, Metastatic Cancer | Phase 3 | NCT06174987 |
| 2028-02-20 | Benralizumab | AstraZeneca, Kyowa Kirin, MedImmune LLC | Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | NCT06512883 |
| 2028-02-20 | Camrelizumab, Apatinib | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen Laboratories | Hepatocellular Carcinoma | Phase 2/3 | NCT06796803 |
| 2028-02-21 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Alzheimer's Disease | Phase 3 | NCT06947941 |
| 2028-02-22 | Semaglutide (Wegovy tablets) | Novo Nordisk | Obesity | Phase 3 | NCT07770841 |
| 2028-02-23 | cagrilintide/semaglutide | Novo Nordisk | Obesity, Type 2 Diabetes | Phase 3 | NCT07564414 |
| 2028-02-24 | Dapagliflozin, Baxdrostat | AstraZeneca, Ono Pharmaceutical, Roche | Chronic Kidney Disease, Hypertension | Phase 3 | NCT06268873 |
| 2028-02-24 | enicepatide | Chugai Pharma, Roche | Obesity, Type 2 Diabetes | Phase 3 | NCT07670416 |
| 2028-02-28 | baricitinib | Eli Lilly, Incyte | Dermatomyositis | Phase 3 | NCT04972760 |
| 2028-02-28 | Oveporexton | Takeda Pharmaceutical Company | Narcolepsy | Phase 2/3 | NCT05816382 |
| 2028-02-28 | SYH2053 | CSPC Pharmaceutical Group | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07465263 |
| 2028-02-28 | remestemcel-L | JCR Pharmaceuticals, Mesoblast | Graft-versus-Host Disease | Phase 3 | NCT07568535 |
| 2028-02-29 | Odronextamab | Regeneron Pharmaceuticals | Follicular Lymphoma | Phase 3 | NCT06091254 |
| 2028-02-29 | Raludotatug Deruxtecan | Daiichi Sankyo, Merck & Co. | Solid Cancer | Phase 2/3 | NCT06161025 |
| 2028-02-29 | GSK 5733584 | GlaxoSmithKline | Neoplasms, Endometrial | Phase 3 | NCT07286331 |
| 2028-02-29 | Zemocimig | Roche | Hemophilia A | Phase 3 | NCT07416604 |
| 2028-02-29 | CMS-D001 | China Medical System, Dermavon Holdings | Psoriasis | Phase 2/3 | NCT07432854 |
| 2028-02-29 | UBT251 | Novo Nordisk, United Bio-Technology (Hengqin) | Type 2 Diabetes | Phase 3 | NCT07653477 |
March 2028
April 2028
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2028-04 (month only) | Lecanemab, Etalanetug | Biogen, Eisai | Alzheimer's Disease | Phase 2/3 | NCT01760005 |
| 2028-04 (month only) | risankizumab | AbbVie, Boehringer Ingelheim | Psoriasis | Phase 3 | NCT04862286 |
| 2028-04 (month only) | Teclistamab | Johnson & Johnson | Multiple Myeloma | Phase 3 | NCT05243797 |
| 2028-04 (month only) | Etalanetug | Eisai | Alzheimer's Disease | Phase 2/3 | NCT05269394 |
| 2028-04 (month only) | Sacituzumab Govitecan | Gilead Sciences | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT05840211 |
| 2028-04 (month only) | Pembrolizumab | Merck & Co. | Progressive Multifocal Leukoencephalopathy | Phase 2/3 | NCT06276504 |
| 2028-04 (month only) | Valbenazine | Neurocrine Biosciences, Tanabe Pharma Corporation | Huntington's Disease | Phase 3 | NCT06312189 |
| 2028-04 (month only) | Ivonescimab | Akeso, Summit Therapeutics | Non-Small Cell Lung Cancer | Phase 3 | NCT06767514 |
| 2028-04 (month only) | retatrutide | Eli Lilly | Obesity | Phase 3 | NCT06859268 |
| 2028-04 (month only) | mirikizumab, Tirzepatide (Zepbound) | Eli Lilly | Ulcerative Colitis, Obesity | Phase 3 | NCT06937086 |
| 2028-04 (month only) | Casdatifan | Arcus Biosciences, Taiho Pharmaceutical | Clear Cell Renal Cell Carcinoma | Phase 3 | NCT07011719 |
| 2028-04 (month only) | Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | NCT07132827 |
| 2028-04 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity, Osteoarthritis | Phase 3 | NCT07153471 |
| 2028-04 (month only) | Adebrelimab | Jiangsu Hengrui Pharmaceuticals | Advanced Cervical Cancer | Phase 3 | NCT07168200 |
| 2028-04 (month only) | Brenipatide | Eli Lilly | Alcohol Use Disorder | Phase 3 | NCT07219953 |
| 2028-04 (month only) | Brenipatide | Eli Lilly | Alcohol Use Disorder | Phase 3 | NCT07219966 |
| 2028-04 (month only) | Methylprednisolone | Pfizer | Hand Osteoarthritis | Phase 3 | NCT07371572 |
| 2028-04 (month only) | QLC7401 | Qilu Pharmaceutical, Suzhou Ribo Life Science | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07450378 |
| 2028-04 (month only) | TARA-002 | Chugai Pharma, Protara Therapeutics | Non-Muscle Invasive Bladder Cancer | Phase 3 | NCT07480356 |
| 2028-04 (month only) | Nab-paclitaxel, Daraxonrasib | Bristol-Myers Squibb, BeOne Medicines, Revolution Medicines | Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT07491445 |
| 2028-04 (month only) | Ticagrelor | AstraZeneca | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07582835 |
| 2028-04 (month only) | sildenafil | Pfizer, Viatris | Pulmonary Arterial Hypertension | Phase 2/3 | NCT07824674 |
| 2028-04-01 | Atezolizumab, Bevacizumab | Chugai Pharma, Roche | Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | NCT06733038 |
| 2028-04-01 | Tislelizumab | BeOne Medicines | Gastric Cancer | Phase 3 | NCT06793917 |
| 2028-04-01 | Obinutuzumab | Roche | Membranous Nephropathy - PLA2R Induced | Phase 2/3 | NCT07163611 |
| 2028-04-05 | HSK44459 | Haisco Pharmaceutical Group | Idiopathic Pulmonary Fibrosis | Phase 3 | NCT07519070 |
| 2028-04-06 | TAR-210 | Johnson & Johnson | Non-Muscle Invasive Bladder Cancer | Phase 3 | NCT06919965 |
| 2028-04-06 | elecoglipron | AstraZeneca, Eccogene | Obesity, Type 2 Diabetes | Phase 3 | NCT07775404 |
| 2028-04-10 | Sotiburafusp alfa | Huabo Biopharm Co. | Non-Small Cell Lung Cancer | Phase 3 | NCT07360132 |
| 2028-04-10 | Sotiburafusp alfa, pemetrexed | Huabo Biopharm Co., Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT07383116 |
| 2028-04-12 | bimekizumab | UCB | Psoriatic Arthritis | Phase 3 | NCT06668181 |
| 2028-04-14 | Atrasentan, Zigakibart | Novartis | IgA Nephropathy, Chronic Kidney Disease | Phase 3 | NCT04573478 |
| 2028-04-15 | Acoramidis | Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca), Bayer, BridgeBio Pharma | Amyloid Cardiomyopathy, Transthyretin-Related | Phase 3 | NCT04988386 |
| 2028-04-18 | Duloxetine | Eli Lilly | ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Drug-Related Side Effects and Adverse Reactions, Musculoskeletal Pain | Phase 3 | NCT06407401 |
| 2028-04-19 | Amdokitug (Yisaituo) | Sunshine Guojian Pharmaceutical | Axial Spondyloarthritis, Non-Radiographic | Phase 3 | NCT07349329 |
| 2028-04-20 | Abemaciclib, Ribociclib, Palbociclib, Giredestrant | Eli Lilly, Novartis, Pfizer | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06065748 |
| 2028-04-24 | Pioglitazone | Takeda Pharmaceutical Company | ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis | Phase 3 | NCT05946564 |
| 2028-04-24 | Rituximab, Golcadomide | Biogen, Chugai Pharma, Roche | Follicular Lymphoma | Phase 3 | NCT06911502 |
| 2028-04-26 | PF-06651600 | Pfizer | Alopecia Areata | Phase 3 | NCT07733765 |
| 2028-04-27 | Roflumilast (Zoryve) | Arcutis Biotherapeutics, Huadong Medicine, Sato Pharmaceutical Co., Ltd. | Atopic Dermatitis | Phase 3 | NCT07916480 |
| 2028-04-28 | Zanidatamab, Eribulin mesylate, Capecitabine | BeOne Medicines, Jazz Pharmaceuticals, Zymeworks | HER2-Positive Breast Cancer, Breast Cancer | Phase 3 | NCT06435429 |
| 2028-04-28 | Pertuzumab | Roche | HER2-Positive Breast Cancer, Breast Cancer | Phase 3 | NCT07377643 |
| 2028-04-30 | Eptinezumab (Vyepti) | H. Lundbeck | Migraine | Phase 3 | NCT05164172 |
| 2028-04-30 | Befotertinib | Betta Pharmaceuticals Co., InventisBio | Non-Small Cell Lung Cancer | Phase 3 | NCT06041776 |
| 2028-04-30 | vedolizumab, infliximab | Takeda Pharmaceutical Company, Johnson & Johnson | Ulcerative Colitis | Phase 3 | NCT06614387 |
| 2028-04-30 | Fulvestrant, Zovegalisib | AstraZeneca, Relay Therapeutics, Inc. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06982521 |
| 2028-04-30 | Clemidsogene lanparvovec | Nippon Shinyaku, REGENXBIO Inc. | Mucopolysaccharidosis Type II | Phase 3 | NCT07236606 |
| 2028-04-30 | Tislelizumab | BeOne Medicines | Nasopharyngeal Carcinoma | Phase 3 | NCT07373990 |
| 2028-04-30 | Tambotatug pelitecan | MediLink Therapeutics (Suzhou) Co., Ltd., Roche | Esophageal Squamous Cell Carcinoma | Phase 3 | NCT07487896 |
| 2028-04-30 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07823608 |
May 2028
June 2028
July 2028
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2028-07 (month only) | Rituximab | Biogen, Chugai Pharma, Roche | Follicular Lymphoma | Phase 3 | NCT05058404 |
| 2028-07 (month only) | Obinutuzumab, zanubrutinib | Roche, BeOne Medicines | Follicular Lymphoma | Phase 3 | NCT05100862 |
| 2028-07 (month only) | Sacituzumab Govitecan | Gilead Sciences | Breast Cancer | Phase 3 | NCT05382299 |
| 2028-07 (month only) | AL8326 | Advenchen Laboratories | Small Cell Lung Cancer | Phase 3 | NCT06247605 |
| 2028-07 (month only) | Anitocabtagene autoleucel | Gilead Sciences | Multiple Myeloma | Phase 3 | NCT06413498 |
| 2028-07 (month only) | Plozasiran | Arrowhead Pharmaceuticals, Sanofi | Hypertriglyceridemia | Phase 3 | NCT06822790 |
| 2028-07 (month only) | Bevacizumab | Roche | Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity, Radiation Effect, Radiation Injury, Radiation Injuries | Phase 3 | NCT06888817 |
| 2028-07 (month only) | Iparomlimab and tuvonralimab | Qilu Pharmaceutical | Metastatic Colorectal Cancer | Phase 3 | NCT07025239 |
| 2028-07 (month only) | Osavampator | Neurocrine Biosciences, Takeda Pharmaceutical Company | Major Depressive Disorder | Phase 3 | NCT07196501 |
| 2028-07 (month only) | baricitinib | Eli Lilly, Incyte | Diabetes Mellitus, Type 1 | Phase 3 | NCT07222332 |
| 2028-07 (month only) | SHR-1918 | Jiangsu Hengrui Pharmaceuticals | Hypercholesterolemia | Phase 2/3 | NCT07404553 |
| 2028-07 (month only) | Saroglitazar | Zydus Lifesciences | Primary Biliary Cholangitis | Phase 3 | NCT07424677 |
| 2028-07 (month only) | Zodasiran | Arrowhead Pharmaceuticals | Homozygous Familial Hypercholesterolemia | Phase 3 | NCT07473843 |
| 2028-07 (month only) | Daratumumab, Torutamig | Johnson & Johnson, Biocad | Multiple Myeloma | Phase 3 | NCT07742215 |
| 2028-07 (month only) | ASC30 | Ascletis Pharma | Obesity, Type 2 Diabetes | Phase 3 | NCT07743450 |
| 2028-07 (month only) | ASC30 | Ascletis Pharma | Obesity | Phase 3 | NCT07743463 |
| 2028-07 (month only) | VK2735 | Viking Therapeutics | Obesity | Phase 3 | NCT07868835 |
| 2028-07 (month only) | Pembrolizumab, pemetrexed | Merck & Co., Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT07915037 |
| 2028-07-01 | Methotrexate, Blinatumomab, Dexamethasone, Ponatinib | Amgen, Incyte, Otsuka Holdings | Acute Lymphoblastic Leukemia | Phase 3 | NCT04530565 |
| 2028-07-01 | Gemcitabine | Eli Lilly | Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8 | Phase 2/3 | NCT04559139 |
| 2028-07-01 | Pembrolizumab, Bevacizumab | Merck & Co., Roche | Endometrial Cancer | Phase 3 | NCT07198074 |
| 2028-07-01 | Disitamab Vedotin, Gemcitabine | Pfizer, RemeGen Co., Ltd., Eli Lilly | MIBC | Phase 3 | NCT07693959 |
| 2028-07-03 | Atezolizumab, tocilizumab, Obrixtamig | Chugai Pharma, Roche, Boehringer Ingelheim | Advanced Cancer | Phase 3 | NCT07929051 |
| 2028-07-04 | zenagamtide | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT07931573 |
| 2028-07-05 | Atezolizumab, Bevacizumab, Alectinib, Cabozantinib, Niraparib, Rucaparib, Venetoclax, Cobimetinib, pemetrexed, Vemurafenib | Chugai Pharma, Roche, Exelixis | Cancer | Phase 3 | NCT03768063 |
| 2028-07-05 | Capsaicin (Qutenza) | Apotex Inc., BCWorld Pharm, Clinect | Neuropathic Pain, Chronic Pain | Phase 3 | NCT05997979 |
| 2028-07-05 | elecoglipron | AstraZeneca, Eccogene | Type 2 Diabetes | Phase 3 | NCT07662109 |
| 2028-07-08 | Rituximab | Biogen, Chugai Pharma, Roche | Interstitial Lung Disease With Systemic Sclerosis | Phase 3 | NCT06549231 |
| 2028-07-12 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07571005 |
| 2028-07-13 | elecoglipron | AstraZeneca, Eccogene | Type 2 Diabetes, Chronic Kidney Disease | Phase 3 | NCT07662135 |
| 2028-07-14 | Bortezomib, Methotrexate, Blinatumomab, Dexamethasone | Janssen, Takeda Pharmaceutical Company, Amgen | Acute Lymphoblastic Leukemia | Phase 3 | NCT03643276 |
| 2028-07-14 | elecoglipron, Dapagliflozin | AstraZeneca, Eccogene, Ono Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07662044 |
| 2028-07-18 | Cadonilimab | Akeso | Locally Advanced Cervical Carcinoma | Phase 3 | NCT07400536 |
| 2028-07-20 | Lenalidomide | Bristol-Myers Squibb, Celgene Corporation | IgG4 Related Disease | Phase 2/3 | NCT07068165 |
| 2028-07-20 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT07735117 |
| 2028-07-21 | Iptacopan | Novartis | Atypical Hemolytic Uremic Syndrome | Phase 3 | NCT05935215 |
| 2028-07-24 | enicepatide | Chugai Pharma, Roche | Obesity, Type 2 Diabetes | Phase 3 | NCT07351045 |
| 2028-07-24 | zenagamtide | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT07931599 |
| 2028-07-26 | survodutide | Boehringer Ingelheim, Zealand Pharma | Obesity | Phase 3 | NCT07850050 |
| 2028-07-31 | Pembrolizumab | Merck & Co. | Non-Muscle Invasive Bladder Cancer | Phase 3 | NCT03711032 |
| 2028-07-31 | Azacitidine (Onureg) | Bristol-Myers Squibb | Myelodysplastic Syndromes | Phase 2/3 | NCT05469737 |
| 2028-07-31 | Sintilimab | Innovent Biologics | Rectal Neoplasms Malignant, Radiotherapy | Phase 2/3 | NCT05484024 |
| 2028-07-31 | N-acetylcysteine | Apotex Inc., Phebra Pty Ltd | Autism Spectrum Disorder | Phase 2/3 | NCT05494398 |
| 2028-07-31 | Camrelizumab, Apatinib | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen Laboratories | Hepatocellular Carcinoma | Phase 3 | NCT06172205 |
| 2028-07-31 | Pozelimab, Cemdisiran | Regeneron Pharmaceuticals, Alnylam Pharmaceuticals | Age-Related Macular Degeneration | Phase 3 | NCT06541704 |
| 2028-07-31 | Lerodalcibep | Everest Medicines (Beijing) Co., Ltd., LIB Therapeutics, Sun Pharmaceutical Industries | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07102511 |
| 2028-07-31 | elecoglipron | AstraZeneca, Eccogene | Obesity, Type 2 Diabetes | Phase 3 | NCT07667803 |
| 2028-07-31 | Tirzepatide (Mounjaro) | Eli Lilly, Tanabe Pharma Corporation | Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 3 | NCT07671248 |
| 2028-07-31 | HS-10380 | Hansoh Pharmaceutical Group | Schizophrenia | Phase 3 | NCT07759869 |
| 2028-07-31 | zenagamtide | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT07797335 |
| 2028-07-31 | Remimazolam | Jiangsu Hengrui Pharmaceuticals | Long-term Sedation for Mechanical Ventilation, Critically Ill Intensive Care Unit Patients | Phase 3 | NCT07880548 |
| 2028-07-31 | zenagamtide | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT07931547 |
August 2028
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2028-08 (month only) | upadacitinib | AbbVie | Takayasu Arteritis (TAK) | Phase 3 | NCT04161898 |
| 2028-08 (month only) | Semaglutide (Ozempic) | Novo Nordisk | Double Diabetes | Phase 3 | NCT05305794 |
| 2028-08 (month only) | Sacubitril/valsartan | Novartis, Otsuka Holdings | Heart Failure | Phase 3 | NCT05508035 |
| 2028-08 (month only) | upadacitinib | AbbVie | Ulcerative Colitis | Phase 3 | NCT05782907 |
| 2028-08 (month only) | upadacitinib | AbbVie | Hidradenitis Suppurativa | Phase 3 | NCT05889182 |
| 2028-08 (month only) | Zanzalintinib | Exelixis | Head and Neck Squamous Cell Carcinoma | Phase 2/3 | NCT06082167 |
| 2028-08 (month only) | fluticasone propionate | GlaxoSmithKline | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT06234345 |
| 2028-08 (month only) | Bevacizumab | Roche | Radionecrosis of Brain, Brain Metastases | Phase 3 | NCT06471465 |
| 2028-08 (month only) | Sacubitril/valsartan | Novartis, Otsuka Holdings | Congenital Heart Disease | Phase 3 | NCT06693674 |
| 2028-08 (month only) | Docetaxel | Sanofi | Triple-negative Breast Cancer | Phase 3 | NCT06795503 |
| 2028-08 (month only) | Ponesimod | Laboratoires Juvisé Pharmaceuticals, Vanda Pharmaceuticals | Psoriasis | Phase 3 | NCT07362017 |
| 2028-08 (month only) | lebrikizumab | Almirall, Eli Lilly | Nummular Eczema | Phase 3 | NCT07542483 |
| 2028-08 (month only) | Pembrolizumab | Merck & Co. | Non-Small Cell Lung Cancer | Phase 3 | NCT07809256 |
| 2028-08-01 | Gabapentin, Naltrexone | Pfizer, Viatris | Alcohol Use Disorder | Phase 3 | NCT05827159 |
| 2028-08-01 | Sacituzumab Govitecan | Gilead Sciences | Metastatic Colorectal Cancer | Phase 2/3 | NCT06243393 |
| 2028-08-01 | Cannabidiol (JZP926) | Jazz Pharmaceuticals | Epilepsy | Phase 2/3 | NCT07723963 |
| 2028-08-01 | Iparomlimab and tuvonralimab | Qilu Pharmaceutical | MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706 | Phase 2/3 | NCT07866313 |
| 2028-08-05 | Uliledlimab | NovaBridge Biosciences, TJ Biopharma Co., Ltd. | Non-Small Cell Lung Cancer | Phase 2/3 | NCT06984588 |
| 2028-08-07 | Finerenone | Bayer | Chronic Kidney Disease | Phase 3 | NCT05457283 |
| 2028-08-07 | enicepatide | Chugai Pharma, Roche | Obesity, Type 2 Diabetes | Phase 3 | NCT07351058 |
| 2028-08-07 | zenagamtide | Novo Nordisk | Obesity, Type 2 Diabetes | Phase 3 | NCT07533175 |
| 2028-08-09 | Lenbelintide | AstraZeneca | Obesity | Phase 3 | NCT07776509 |
| 2028-08-09 | Lenbelintide | AstraZeneca | Obesity | Phase 3 | NCT07784270 |
| 2028-08-10 | Lenalidomide, zanubrutinib | Bristol-Myers Squibb, Celgene Corporation, BeOne Medicines | Diffuse Large B-Cell Lymphoma | Phase 3 | NCT06522555 |
| 2028-08-11 | JNJ-78934804 | Johnson & Johnson | Ulcerative Colitis | Phase 3 | NCT07577856 |
| 2028-08-11 | Lenbelintide | AstraZeneca | Obesity | Phase 3 | NCT07784725 |
| 2028-08-13 | Venetoclax, Rituximab | AbbVie, Roche, Biogen | Diffuse Large B-Cell Lymphoma | Phase 2/3 | NCT03984448 |
| 2028-08-14 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07481630 |
| 2028-08-14 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07509307 |
| 2028-08-15 | Chidamide | Chipscreen Biosciences, GNT Biotech & Medicals, HUYABIO International, LLC. | T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | NCT07774377 |
| 2028-08-16 | Methylprednisolone | Pfizer | Acute Myocarditis | Phase 3 | NCT06522100 |
| 2028-08-17 | Sacituzumab Tirumotecan, Dexamethasone | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT06305754 |
| 2028-08-17 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | NCT07362186 |
| 2028-08-18 | Pasritamig, JNJ-87189401 | Johnson & Johnson | Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer | Phase 3 | NCT07164443 |
| 2028-08-20 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Nasopharyngeal Carcinoma | Phase 3 | NCT06561763 |
| 2028-08-21 | bimekizumab | UCB | Psoriasis | Phase 3 | NCT06425549 |
| 2028-08-21 | Berobenatide | Pfizer | Obesity, Type 2 Diabetes | Phase 3 | NCT07915609 |
| 2028-08-22 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07919678 |
| 2028-08-24 | Seltorexant | Johnson & Johnson | Major Depressive Disorder | Phase 3 | NCT07573176 |
| 2028-08-25 | Anifrolumab | AstraZeneca, MedImmune LLC | Systemic Lupus Erythematosus | Phase 3 | NCT07751848 |
| 2028-08-26 | Fazirsiran | Arrowhead Pharmaceuticals, Takeda Pharmaceutical Company | Alpha-1 Antitrypsin Deficiency | Phase 3 | NCT06165341 |
| 2028-08-30 | Quetiapine (Seroquel) | Cheplapharm Arzneimittel GmbH, Luye Pharma Group | Treatment Resistant Depression (TRD) | Phase 3 | NCT07760168 |
| 2028-08-30 | Crisugabalin | Haisco Pharmaceutical Group | Diabetic Peripheral Neuropathic Pain | Phase 3 | NCT07859111 |
| 2028-08-31 | Rituximab | Biogen, Chugai Pharma, Roche | Relapsed/Refractory Marginal Zone Lymphoma | Phase 3 | NCT06082102 |
| 2028-08-31 | Ribociclib, Palbociclib | Novartis, Pfizer | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06377852 |
| 2028-08-31 | Everolimus | Novartis | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06680921 |
| 2028-08-31 | Sonrotoclax | BeOne Medicines | Mantle Cell Lymphoma | Phase 3 | NCT06742996 |
| 2028-08-31 | NTQ1062 | Sino Biopharmaceutical | HR+/HER2- Metastatic Breast Cancer | Phase 3 | NCT07393321 |
| 2028-08-31 | Beruzatatug pelitecan | BioNTech, MediLink Therapeutics (Suzhou) Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT07416994 |
| 2028-08-31 | Dexamethasone | Knee Arthroscopy | Phase 3 | NCT07674576 | |
| 2028-08-31 | Tenofovir alafenamide/emtricitabine, ACC017 | Gilead Sciences, Jiangsu Aidea Pharmaceutical Group | HIV | Phase 3 | NCT07711223 |
| 2028-08-31 | Tabirafusp tedromer | Kodiak Sciences Inc. | Diabetic Macular Edema | Phase 3 | NCT07734844 |
September 2028
October 2028
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2028-10 (month only) | tofacitinib, tocilizumab | Pfizer, Chugai Pharma, Roche | Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | NCT04871191 |
| 2028-10 (month only) | Nab-paclitaxel, Tislelizumab | Bristol-Myers Squibb, BeOne Medicines | Head and Neck Squamous Cell Carcinomas | Phase 3 | NCT05582265 |
| 2028-10 (month only) | pegunigalsidase alfa | Chiesi Farmaceutici, Protalix BioTherapeutics, Inc. | Fabry Disease | Phase 2/3 | NCT06328608 |
| 2028-10 (month only) | Adebrelimab, pemetrexed | Jiangsu Hengrui Pharmaceuticals, Eli Lilly | Non-Small Cell Lung Cancer | Phase 2/3 | NCT06335355 |
| 2028-10 (month only) | SHR-1819 | Jiangsu Hengrui Pharmaceuticals | Prurigo Nodularis | Phase 2/3 | NCT06554509 |
| 2028-10 (month only) | Dexamethasone | Intensive Care Pediatric | Phase 3 | NCT06722118 | |
| 2028-10 (month only) | Bemdaneprocel (MSK-DA01) | Bayer, BlueRock Therapeutics | Parkinson's Disease | Phase 3 | NCT06944522 |
| 2028-10 (month only) | Rinatabart sesutecan (Rina-S) | Genmab | Ovarian Cancer | Phase 3 | NCT07225270 |
| 2028-10 (month only) | retatrutide | Eli Lilly | Obesity, Type 2 Diabetes | Phase 3 | NCT07357415 |
| 2028-10 (month only) | Tislelizumab | BeOne Medicines | Adenocarcinoma | Phase 3 | NCT07385703 |
| 2028-10 (month only) | apraglutide | Ironwood Pharmaceuticals | Short Bowel Syndrome | Phase 3 | NCT07742735 |
| 2028-10 (month only) | VK2735 | Viking Therapeutics | Obesity, Type 2 Diabetes | Phase 3 | NCT07868939 |
| 2028-10 (month only) | Mesutoclax | Beijing InnoCare Pharma Tech Co. | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | Phase 3 | NCT07896590 |
| 2028-10-01 | Venetoclax, Obinutuzumab | AbbVie, Roche | Chronic Lymphocytic Leukemia | Phase 3 | NCT04269902 |
| 2028-10-01 | Atezolizumab | Chugai Pharma, Roche | Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma | Phase 2/3 | NCT05058651 |
| 2028-10-01 | Gilteritinib, Venetoclax, Azacitidine | Astellas Pharma, AbbVie, Roche | Acute Myeloid Leukemia | Phase 2/3 | NCT07425808 |
| 2028-10-04 | etranacogene dezaparvovec | CSL Behring, uniQure | Hemophilia B | Phase 3 | NCT06003387 |
| 2028-10-05 | Anifrolumab | AstraZeneca, MedImmune LLC | Systemic Lupus Erythematosus | Phase 3 | NCT05835310 |
| 2028-10-10 | Pozelimab, Cemdisiran | Regeneron Pharmaceuticals, Alnylam Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | NCT05744921 |
| 2028-10-10 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07668414 |
| 2028-10-13 | Enlicitide | Merck & Co. | Atherosclerotic Cardiovascular Disease, Hypercholesterolemia | Phase 3 | NCT06492291 |
| 2028-10-13 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07932925 |
| 2028-10-15 | Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) | Chugai Pharma, Pfizer, Verastem, Inc. | Ovarian Cancer | Phase 3 | NCT06072781 |
| 2028-10-17 | Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate | Chiesi Farmaceutici | Asthma | Phase 3 | NCT07546981 |
| 2028-10-18 | etanercept | Amgen, Pfizer | SAPHO Syndrome | Phase 2/3 | NCT06011889 |
| 2028-10-20 | petrelintide | Roche, Zealand Pharma | Obesity | Phase 3 | NCT07843485 |
| 2028-10-21 | Rimegepant (Nurtec ODT) | Eisai, Pfizer | Migraine | Phase 3 | NCT07729462 |
| 2028-10-25 | Ulotaront | Otsuka Holdings | Generalized Anxiety Disorder | Phase 3 | NCT07767903 |
| 2028-10-27 | Iptacopan | Novartis | IC-MPGN | Phase 3 | NCT05755386 |
| 2028-10-27 | Ferumoxytol | Azurity Pharmaceuticals | Glioblastoma | Phase 3 | NCT07461948 |
| 2028-10-30 | tulisokibart | Merck & Co. | Crohn's Disease | Phase 3 | NCT06430801 |
| 2028-10-30 | Trametinib, Dabrafenib | Novartis | Ameloblastoma | Phase 2/3 | NCT06819605 |
| 2028-10-30 | S-1 | Nordic Group B.V., Taiho Pharmaceutical | Gastric Cancer | Phase 3 | NCT07366528 |
| 2028-10-30 | Ocankitug | Keymed Biosciences, Shanghai JMT-Bio | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | NCT07420257 |
| 2028-10-31 | Osimertinib, Durvalumab | AstraZeneca | Non-Small Cell Lung Cancer | Phase 3 | NCT03833154 |
| 2028-10-31 | Ruxolitinib (Jakafi) | Incyte, Novartis | Polycythemia Vera | Phase 3 | NCT04116502 |
| 2028-10-31 | Pembrolizumab, Adagrasib | Merck & Co., Bristol-Myers Squibb, Zai Lab | Non-Small Cell Lung Cancer | Phase 2/3 | NCT04613596 |
| 2028-10-31 | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Aging, Arterial Stiffness | Phase 2/3 | NCT06506422 |
| 2028-10-31 | Dexamethasone | Influenza | Phase 3 | NCT06528444 | |
| 2028-10-31 | Furmonertinib | Allist Pharmaceuticals, ArriVent BioPharma | Non-Small Cell Lung Cancer | Phase 3 | NCT07010419 |
| 2028-10-31 | Tislelizumab, pemetrexed | BeOne Medicines, Eli Lilly | Non-Small Cell Lung Cancer | Phase 2/3 | NCT07131319 |
| 2028-10-31 | Bevacizumab, IBI363 | Roche, Innovent Biologics, Takeda Pharmaceutical Company | Colorectal Cancer | Phase 3 | NCT07722494 |
November 2028
December 2028
Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.